Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Rick Rodgers
AddedMar 31, 2024
UpdatedMay 31, 2026
Rick Rodgers

Rick Rodgers

Board Member, Ocuphire Pharma

LinkedIn

Rick Rodgers's Career

Ocuphire Pharma
Ocuphire Pharma

Farmington Hills, MI, US

Board Member· Board
Ardelyx
Ardelyx

Fremont, CA, US

Board Member· Board
Novavax
Novavax

Gaithersburg, MD, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Rick Rodgers's Career

Ocuphire Pharma
Ocuphire Pharma
Public$24.6M82018Farmington Hills, MI, US
Board Member· Board

Leadership at Ocuphire Pharma

Sean AinsworthSean AinsworthBoard Member
Mina SoochMina SoochBoard Member
Cam GallagherCam GallagherBoard Member
Alan MeyerAlan MeyerBoard Member
Susan BentonSusan BentonBoard Member
Dr James S J ManusoDr James S J ManusoBoard Member

Similar to Ocuphire Pharma

Ocumension TherapeuticsOcumension TherapeuticsShanghai, Shanghai, CNPharmaceuticals, Therapiesest. 2017Ocumension TherapeuticsShanghai, Shanghai, CN · est. 2017

Ocumension Therapeutics: A dedicated platform for developing and commercializing ophthalmic therapies.

Public · $200M175
OcuCure TherapeuticsOcuCure TherapeuticsRoanoke, VA, USEye Drops, Pharmaceuticalsest. 2005OcuCure TherapeuticsRoanoke, VA, US · est. 2005

OcuCure Therapeutics: Developing innovative eye drops for age-related and diabetic eye diseases since 2005.

Public · $3.3M8
EyePointEyePointWatertown, MA, USDrug Devicesest. 2008EyePointWatertown, MA, US · est. 2008

EyePoint Pharmaceuticals, a global biopharmaceutical firm, develops drug devices for chronic eye disorders.

Public · $653.8M144
Ocular TherapeutixOcular TherapeutixBedford, MA, USOphthalmic Therapiesest. 2006Ocular TherapeutixBedford, MA, US · est. 2006

Ocular Therapeutix, Inc.: Global biopharma innovator in hydrogel-based ophthalmic therapies.

Public · $386.5M274
Ardelyx
Ardelyx
Public$471.4M1332007Fremont, CA, US
Board Member· Board

Leadership at Ardelyx

Jan LundbergJan LundbergBoard Member
Michael RaabMichael RaabBoard Member
Peter G. SchultzPeter G. SchultzCo-Founder
Geoffrey A. BlockGeoffrey A. BlockBoard Member
Onaiza Cadoret-ManierOnaiza Cadoret-ManierBoard Member
Dominique CharmotDominique CharmotCo-Founder

Similar to Ardelyx

Elcelyx TherapeuticsElcelyx TherapeuticsSan Diego, CA, USPharmaceuticalsest. 2010Elcelyx TherapeuticsSan Diego, CA, US · est. 2010

Elcelyx Therapeutics develops nutrient-based solutions for weight management and metabolic disorders.

Series E · $96.8M9
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
Novavax
Novavax
Public$2.7B2k1987Gaithersburg, MD, US
Board Member· Board

Leadership at Novavax

Gregg AltonGregg AltonBoard Member
John C. JacobsJohn C. JacobsBoard Member
James F. YoungJames F. YoungBoard Member
Margaret McGlynnMargaret McGlynnBoard Member
Michael McManusMichael McManusBoard Member
Dave MottDave MottBoard Member

Similar to Novavax

Dynavax TechnologiesDynavax TechnologiesBerkeley, CA, USVaccinesest. 1996Dynavax TechnologiesBerkeley, CA, US · est. 1996

Dynavax, a US biopharmaceutical firm, develops and markets novel vaccines, including a hepatitis B vaccine and COVID-19 research.

Public · $1.4B351
GeoVax LabsGeoVax LabsSmyrna, GA, USVaccinesest. 2001GeoVax LabsSmyrna, GA, US · est. 2001

GeoVax Labs Inc.: A biotech firm specializing in the development and commercialization of vaccines for HIV-1 and other diseases.

Public · $28M14
Emergent BioSolutionsEmergent BioSolutionsGaithersburg, MD, USTherapeutics, Vaccinesest. 1998Emergent BioSolutionsGaithersburg, MD, US · est. 1998

American biopharmaceutical company developing vaccines and therapeutics in Gaithersburg, MD.

Public · $36.5M2.5k
PaxVaxPaxVaxRedwood City, CA, USVaccinesest. 2006PaxVaxRedwood City, CA, US · est. 2006

PaxVax, a US-based vaccine start-up, develops oral vaccines for key diseases using proprietary adenovirus tech.

Private Equity · $234.6M375

People Similar to Rick Rodgers

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao